MaaT Pharma Advances NSCLC Study with First Patient Randomized in IMMUNOLIFE Trial
Event summary
- First patient randomized in the IMMUNOLIFE Phase 2 trial evaluating MaaT033 in combination with Regeneron’s Cemiplimab for advanced NSCLC patients with antibiotic-induced dysbiosis.
- Trial aims to enroll 162 patients across 14 centers in France, with primary results expected in late 2030.
- Interim futility analysis scheduled for H1 2027 after 81 patients are randomized.
- IMMUNOLIFE is part of MaaT Pharma’s exploratory strategy, alongside the PICASSO trial for metastatic melanoma.
- PICASO topline results delayed to H1 2026, originally expected in Q4 2025.
The big picture
MaaT Pharma’s IMMUNOLIFE trial represents a strategic push into immuno-oncology, targeting a well-defined patient population with antibiotic-induced dysbiosis. The study’s success could validate the company’s microbiome ecosystem therapies as adjuncts to immunotherapy, potentially expanding their application in solid tumors. The delay in PICASSO results highlights the complexities of clinical trials in oncology, but the combined data from both studies will be critical in shaping MaaT Pharma’s future development pipeline.
What we're watching
- Trial Execution
- Whether MaaT Pharma can maintain the pace of patient enrollment and meet the interim futility analysis timeline in H1 2027.
- Strategic Shifts
- How the outcomes of IMMUNOLIFE and PICASSO will inform MaaT Pharma’s clinical development strategy for MaaT034.
- Regulatory Dynamics
- The potential impact of the French National Research Agency’s funding on the trial’s progress and outcomes.
Related topics